Mark L. Fuerst
Staff Correspondent
Shorter hepatitis C regimen effective in black patients
More patients could take advantage of shorter direct-acting antiviral treatment duration.
Hepatitis C virus screening remains low among baby boomers
Females, Hispanics screened less often for highly curable infection.
Hidden chronic hepatitis C infections remain hard to detect
With the advent of new direct-acting antiviral agents, HCV treatment has greatly improved, making identification of infected individuals even more imperative.
HCV screening common but follow-up lacking in young opioid users
More effort needed to integrate screening with follow-up care to prevent spread of the virus.
Asthma, diabetes link tied to which diagnosis comes first
Association between the diseases “is complex, not just inverse,” according to researchers.
Underserved HCV patients benefiting from telemedicine
An innovative telemedicine model could substantially reduce the burden of chronic hepatitis C infection.
Systematic review: DAAs provide cost-effective treatment for hepatitis C
Timely treatment with direct-acting antivirals is highly cost-effective in virtually all patients infected with HCV.
Triple directing-acting combination treats decompensated liver disease
A combination of three drugs successfully treats HCV-infected patients with advanced liver disease.
Liver transplant recipients with HCV fare well under drug combo
Hepatitis C virus infection in liver transplant recipients can be treated with ledipasvir and sofosbuvir without ribavirin.
HBV reactivation with direct acting antivirals for HCV is highly manageable
New study indicates early recognition of HBV-HCV co-infection can lead to prompt treatment of HBV reactivation.